| Name | Title | Contact Details |
|---|
Must be 21+ We aim higher for the wellness of our customers, through the power of cannabis.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
Integrated Health Plan Inc is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
St. Paul County Family and Community Support Services is a St Paul, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Muhlenberg Regional Medical Center is a Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.